BioCentury
ARTICLE | Company News

AMAG Pharmaceuticals, MSMB Capital Management LLC deal

August 15, 2011 7:00 AM UTC

AMAG said its board unanimously rejected an unsolicited offer from shareholder MSMB Capital to acquire AMAG for $18 per share, or about $380.9 million in cash. AMAG said its board determined that MSMB...